Completed

1

20

Canada

Gamma-Secretase Inhibitor RO4929097, RO4929097, Cediranib Maleate, AZD2171, Recentin, Pharmacological Study, pharmacological studies, Laboratory Biomarker Analysis

National Cancer Institute (NCI)

Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Solid Neoplasm, Male Breast Carcinoma, Recurrent Adult Brain Neoplasm, Recurrent Breast Carcinoma, Recurrent Colon Carcinoma, Recurrent Melanoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Carcinoma, Recurrent Rectal Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IIIA Colon Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Rectal Cancer, Stage IIIA Skin Melanoma, Stage IIIB Breast Cancer, Stage IIIB Colon Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Rectal Cancer, Stage IIIB Skin Melanoma, Stage IIIC Breast Cancer, Stage IIIC Colon Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Rectal Cancer, Stage IIIC Skin Melanoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Ovarian Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer

09/14

09/14